---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-087545"
form_type: "8-K"
ticker: "ACXP"
cik: "0001736243"
company_name: "Acurx Pharmaceuticals, Inc."
filed_at: "2024-08-09T23:59:59+00:00"
generated_at: "2026-05-31T10:27:05.912906+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Acurx Q2 net loss $4.1M, cash $6.4M; FDA confirms Phase 3 readiness for ibezapolstat

## Summary
- Net loss of $4.1M ($0.26/diluted share) for Q2 2024 vs. $3.4M ($0.28) in Q2 2023.
- Cash $6.4M at June 30, 2024, down from $7.5M at Dec 31, 2023; raised $0.3M via ATM in Q2.
- R&D expenses $1.8M (Q2 2024) vs $1.7M (Q2 2023); G&A $2.3M vs $1.7M.
- Completed End-of-Phase 2 FDA meeting; agreement on Phase 3 and NDA plan for ibezapolstat (IBZ) for C. difficile.
- USPTO granted IBZ patent expiring June 2042 covering reduced recurrence and microbiome health.

## SEC filing metadata
- accession: 0001104659-24-087545
- form_type: 8-K
- ticker: ACXP
- cik: 0001736243
- company_name: Acurx Pharmaceuticals, Inc.
- filed_at: 2024-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736243/000110465924087545/0001104659-24-087545-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736243/000110465924087545/tm2421278d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-087545
- JSON: https://secwatch.observer/filing/0001104659-24-087545.json
- Plain text: https://secwatch.observer/filing/0001104659-24-087545.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.